Internal Medicine, Medical Oncology · Hackensack, NJ
NPI
1225418866
Since 2015
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
92 2nd St
Hackensack, NJ, 07601
Phone (551) 996-8704
Groups this clinician bills Medicare through
Medicare paid, 2024
$399K
7,464 services
Medicare patients, 2024
462
Average age 75
Drug cost, 2024
$14.5M
2,126 prescriptions
Company payments, 2025
$471
From 8 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Harsh Parmar was code J0885 (injection, epoetin alfa, (for non-esrd use), 1000 units), 2,600 times for 26 patients. In total Harsh Parmar billed 7,464 services in 29 codes, and Medicare paid $399K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-01-26.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2,600 | 26 | $6.36 | $17K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 1,638 | 398 | $13.87 | $23K |
| 99215 Office E&M - Established | Office | 1,189 | 319 | $151.90 | $181K |
| 99214 Office E&M - Established | Office | 664 | 284 | $104.88 | $70K |
| Q5111 Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | Office | 396 | 20 | $107.80 | $43K |
| Q5108 Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | Office | 156 | 11 | $109.94 | $17K |
| 99233 Hospital E&M - Subsequent | Facility | 151 | 37 | $100.08 | $15K |
| 96372 Injection Administration | Office | 104 | 48 | $11.85 | $1,232 |
| 99232 Hospital E&M - Subsequent | Facility | 98 | 50 | $66.53 | $6,520 |
| 99223 Hospital E&M - Initial | Facility | 59 | 53 | $143.42 | $8,462 |
| 99222 Hospital E&M - Initial | Facility | 30 | 27 | $106.16 | $3,185 |
| 85097 Test - Miscellaneous | Office | 20 | 20 | $60.63 | $1,213 |
| 99238 Hospital Discharge Management | Facility | 19 | 17 | $68.91 | $1,309 |
| 99205 Office E&M - New | Office | 18 | 18 | $191.06 | $3,439 |
| 38220 Other Organ Systems | Office | 17 | 17 | $70.24 | $1,194 |
By year: 2022 $315K for 5,742 services; 2023 $369K for 9,683 services; 2024 $399K for 7,464 services.
Lab tests billed to Medicare, 2022
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 1,215 | 302 | $7.53 | $9,143 |
| 85027 Blood Count | 79 | 55 | $6.25 | $493 |
Medicare prescription drug claims, 2024
In 2024, the drug Harsh Parmar prescribed most often to Medicare patients was Pomalyst (Pomalidomide), with 421 prescriptions and refills. In total Harsh Parmar wrote 2,126 Medicare prescriptions that cost $14.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Pomalyst Pomalidomide | 421 | 422 | 100 | $8.1M |
| Dexamethasone Generic | 279 | 356 | 105 | $3,109 |
| Revlimid Lenalidomide | 239 | 239 | 78 | $3.7M |
| Valacyclovir Valacyclovir Hcl | 212 | 529 | 96 | $11K |
| Acyclovir Generic | 148 | 323 | 62 | $2,150 |
| Lenalidomide Generic | 85 | 85 | 33 | $1.0M |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 74 | 92 | 24 | $321 |
| Ninlaro Ixazomib Citrate | 42 | 42 | Under 11 | $539K |
| Tramadol Hcl Generic | 41 | 41 | 24 | $120 |
| Eliquis Apixaban | 36 | 45 | 13 | $25K |
| Ondansetron Hcl Generic | 33 | 33 | 20 | $175 |
| Xarelto Rivaroxaban | 33 | 53 | Under 11 | $28K |
| Gabapentin Generic | 32 | 46 | 11 | $238 |
| Prednisone Generic | 24 | 24 | 12 | $42.74 |
| Levofloxacin Generic | 23 | 25 | 22 | $77.15 |
Brand drugs: - claims; generic drugs: 1,277 claims; opioid claims: 55.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Harsh Parmar $471 ($471 in general payments such as food, travel and fees) from 8 companies. The largest payer was Pfizer Inc. with $152.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.